Sentinel lymph node molecular ultrastaging in patients with melanoma: A systematic review and meta-analysis of prognosis

Journal of Clinical Oncology

Volumn 25, Issue 12, 2007, Pages 1588-1595

  Mocellin, Simone ^a   Hoon, Dave S B ^a   Pilati, Pierluigi ^a   Rossi, Carlo R ^a   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MELANOMA; META ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REVIEW; SENTINEL LYMPH NODE BIOPSY; SYSTEMATIC REVIEW; FEMALE; LYMPH NODE; LYMPH NODE METASTASIS; MALE; METASTASIS; MORTALITY; PATHOLOGY; SENSITIVITY AND SPECIFICITY; SKIN TUMOR; SURVIVAL;

DNA;

DNA, NEOPLASM; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 34248212172     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.4573     Document Type: Review

References (45)

1. Morton DL: Lymphatic mapping and sentinel lymphadenectomy for melanoma: Past, present, and future. Ann Surg Oncol 8:22S-28S, 2001 (9 suppl)
2. Singletary SE, Connolly JL: Breast cancer staging: Working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 56:37-47, 2006
3. Balch CM, Soong SJ, Atkins MB, et al: An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54:131-149, 2004
4. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
5. Thompson JF, Stretch JR, Uren RF, et al: Sentinel node biopsy for melanoma: Where have we been and where are we going? Ann Surg Oncol 11:147S-151S, 2004 (3 suppl)
6. Gietema HA, Vuylsteke RJ, de Jonge IA, et al: Sentinel lymph node investigation in melanoma: Detailed analysis of the yield from step sectioning and immunohistochemistry. J Clin Pathol 57:618-620, 2004
7. Ulmer A, Fischer JR, Schanz S, et al: Detection of melanoma cells displaying multiple genomic changes in histopathologically negative sentinel lymph nodes. Clin Cancer Res 11:5425-5432, 2005
8. Lugo TG, Braun S, Cote RJ, et al: Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol 21:2609-2615, 2003
9. Mocellin S, Keilholz U, Rossi CR, et al: Circulating tumor cells: The 'leukemic phase' of solid cancers. Trends Mol Med 12:130-139, 2006
10. Pawlik TM, Ross MI, Gershenwald JE: Lymphatic mapping in the molecular era. Ann Surg Oncol 11:362-374, 2004
11. Prichard RS, Dijkstra B, McDermott EW, et al: The role of molecular staging in malignant melanoma. Eur J Surg Oncol 29:306-314, 2003
12. Davids V, Kidson SH, Hanekom GS: Melanoma patient staging: Histopathological versus molecular evaluation of the sentinel node. Melanoma Res 13:313-324, 2003
13. Cochran AJ, Starz H, Ohsie SJ, et al: Pathologic reporting and special diagnostic techniques for melanoma. Surg Oncol Clin N Am 15:231-251, 2006
14. Ross MI: Early-stage melanoma: Staging criteria and prognostic modeling. Clin Cancer Res 12:2312S-2319s, 2006 (7 pt 2)
15. Sutton AJ, Abrams KR, Jones DR, et al: Methods for Meta-Analysis in Medical Research. New York, NY, Wiley, 2000
16. Alderson P, Green S, Higgins JPT: Cochrane Reviewers' Handbook 4.2.2. New York, NY, Wiley, 2004
17. Mocellin S, Hoon DS, Ambrosi A, et al: The prognostic value of circulating tumor cells in patients with melanoma: A systematic review and meta-analysis. Clin Cancer Res 12:4605-4613, 2006
18. Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815-2834, 1998
19. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986
20. Thompson SG, Sharp SJ: Explaining heterogeneity in meta-analysis: A comparison of methods. Stat Med 18:2693-2708, 1999
21. Easterbrook PJ, Berlin JA, Gopalan R, et al: Publication bias in clinical research. Lancet 337:867-872, 1991
22. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634, 1997
23. Dupont WD, Plummer WD Jr: Power and sample size calculations: A review and computer program. Control Clin Trials 11:116-128, 1990
24. Starz H, Haas CJ, Schulz GM, et al: Tyrosinase RT-PCR as a supplement to histology for detecting melanoma and nevus cells in paraffin sections of sentinel lymph nodes. Mod Pathol 16:920-929, 2003
25. Rimoldi D, Lemoine R, Kurt AM, et al: Detection of micrometastases in sentinel lymph nodes from melanoma patients: Direct comparison of multimarker molecular and immunopathological methods. Melanoma Res 13:511-520, 2003
26. Mangas C, Hilari JM, Paradelo C, et al: Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptase- polymerase chain reaction for tyrosinase in melanoma patients. Ann Surg Oncol 13:910-918, 2006
27. Takeuchi H, Morton DL, Kuo C, et al: Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 22:2671-2680, 2004
28. Palmieri G, Ascierto PA, Cossu A, et al: Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay. J Clin Oncol 19:1437-1443, 2001
29. Kuo CT, Hoon DS, Takeuchi H, et al: Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol 21:3566-3572, 2003
30. Goydos JS, Patel KN, Shih WJ, et al: Patterns of recurrence in patients with melanoma and histologically negative but RT-PCR-positive sentinel lymph nodes. J Am Coll Surg 196:196-204, 2003; discussion 204-205
31. Scoggins CR, Ross MI, Reintgen DS, et al: Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 24:2849-2857, 2006
32. Shivers SC, Wang X, Li W, et al: Molecular staging of malignant melanoma: Correlation with clinical outcome. JAMA 280:1410-1415, 1998
33. Blaheta HJ, Ellwanger U, Schittek B, et al: Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 114:637-642, 2000
34. Boi S, Cristofolini P, Togni R, et al: Detection of nodal micrometastases using immunohistochemistry and PCR in melanoma of the arm and trunk. Melanoma Res 12:147-153, 2002
35. Abrahamsen HN, Sorensen BS, Nexo E, et al: Pathologic assessment of melanoma sentinel nodes: A role for molecular analysis using quantitative real-time reverse transcription-PCR for MART-1 and tyrosinase messenger RNA. Clin Cancer Res 11:1425-1433, 2005
36. Romanini A, Manca G, Pellegrino D, et al: Molecular staging of the sentinel lymph node in melanoma patients: Correlation with clinical outcome. Ann Oncol 16:1832-1840, 2005
37. Goydos JS, Ravikumar TS, Germino FJ, et al: Minimally invasive staging of patients with melanoma: Sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction. J Am Coll Surg 187:182-188, 1998; discussion 188-190
38. Giese T, Engstner M, Mansmann U, et al: Quantification of melanoma micrometastases in sentinel lymph nodes using real-time RT-PCR. J Invest Dermatol 124:633-637, 2005
39. Bostick PJ, Morton DL, Turner RR, et al: Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 17: 3238-3244, 1999
40. Ulrich J, Bonnekoh B, Bockelmann R, et al: Prognostic significance of detecting micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies: Lessons from 322 consecutive melanoma patients. Eur J Cancer 40:2812-2819, 2004
41. Kammula US, Ghossein R, Bhattacharya S, et al: Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction-staged sentinel lymph nodes from melanoma patients. J Clin Oncol 22:3989-3996, 2004
42. Ribuffo D, Gradilone A, Vonella M, et al: Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma. Ann Surg Oncol 10:396-402, 2003
43. Blaheta HJ, Schittek B, Breuninger H, et al: Detection of melanoma micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. Am J Surg Pathol 23:822-828, 1999
44. Blaheta HJ, Roeger S, Sotlar K, et al: Additional reverse transcription-polymerase chain reaction of peripheral slices is not superior to analysis of the central slice in sentinel lymph nodes from melanoma patients. Br J Dermatol 150:477-483, 2004
45. Li W, Stall A, Shivers SC, et al: Clinical relevance of molecular staging for melanoma: Comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg 231:795-803, 2000